Dallas, Texas 75247

  • Healthy

Purpose:

The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466 on the exposure of metoprolol, midazolam and bupropion


Study summary:

On Day 1, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK sampling will be performed for 48 hours. On Day 3, bupropion will be dosed as a single oral dose and PK sampling will be performed for 48 hours. On Days 5-18, subjects will be dosed with Lu AG06466 once daily. On Day 15, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK sampling will be performed for 48 hours. On Day 17, bupropion will be dosed as a single oral dose and PK sampling will be performed for 48 hours.


Criteria:

Inclusion Criteria: - Body mass index (BMI) of 18.5 to 30 kg/m2 (inclusive) at the Screening and Baseline Visits Exclusion Criteria: - The subject has any concurrent disorder that may affect the pharmacological target or absorption, distribution, or elimination of the investigational medicinal product. Other in- and exclusion criteria may apply


NCT ID:

NCT04713254


Primary Contact:

Study Director
Email contact via H. Lundbeck A/S
LundbeckClinicalTrials@Lundbeck.com


Backup Contact:

N/A


Location Contact:

Dallas, Texas 75247
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.